• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Merit Medical must face shareholder lawsuit

Merit Medical must face shareholder lawsuit

March 31, 2021 By Sean Whooley

merit medicalA federal judge in California quashed a bid by Merit Medical to dismiss a lawsuit alleging misrepresentation of success to stockholders.

The consolidated class action complaint states two claims for securities fraud, alleging that Merit CEO Fred P. Lampropoulos and CFO Raul Parra, plus the company itself, made multiple misrepresentations to investors that resulted in substantial losses to members of the class, according to court documents.

The stockholders claim Merit made false statements regarding its acquisitions of Cianna (a $200 million deal in October 2018) and Vascular Insights (a $60 million deal two months later). Those statements were allegedly made during investor calls and in press releases, along with SEC forms and letters to investors in February, March, April and July of 2019.

Plaintiffs claimed that Merit misrepresented the success of the transition and integration with Cianna, including product sales numbers and the status of Cianna’s sales team.

The complaint alleges that half of the items planned for integration were not integrated by April 23, 2019, resulting in over 20% of the sales force quitting and the subsequent decline of 25%-30% in sales in the western region. Merit later admitted that the acquisition didn’t pan out the way it wanted and resulted in “some painful lessons,” according to the recommendation that U.S. magistrate judge Autumn Spaeth made to U.S. District Judge David O. Carter of California’s central district.

The suit also alleges that Merit misrepresented the sales performance of Vascular Insights’ ClariVein line of catheters, whose primary purpose — the treatment of varicose veins — exceeded its FDA approval. The investors claim Merit’s leaders made “materially false and misleading” statements about ClariVein, despite knowing that the company had not received a single order for the product during the first half of 2019 and that insurance companies were not covering it.

They also state that false statements made by Merit inflated the price of its common stock, which reached $62.60 per share on April 11, 2019, the peak of the “class” period. At the end of that period, the price was $20.66, representing a 67% loss in value, the judge’s order noted.

Spaeth recommended that Carter deny Merit’s motion to dismiss. Merit responded by claiming that the plaintiffs’ lawsuit fails to show that the company made material misstatements about the acquisitions.

Merit alleges that the plaintiffs were off-base in their complaint that Merit’s revenue guidance for 2019 was unattainable because of problems with the acquisition. The company said it missed those projections by $16 million, or 1.6%, which it says is, under law, immaterial. Spaeth agreed.

Merit also said that while ClariVein’s low sales were viewed as material because of the missed guidance by 25% to 32%, the product was expected to bring in just 1% of the company’s total sales. Merit alleges that the $2.5 million miss on ClariVein represented 0.2% of the low end of its projected 2019 revenue.

Merit also claims the plaintiffs failed to provide facts regarding Lampropoulos and Parra and their alleged knowledge of whether statements they made were false or misleading at the time.

“Plaintiffs’ individual allegations do not raise the necessary strong inference of scienter, nor do they do so when viewed collectively and holistically,” Merit wrote in the objection. “There is no plausible motive (as the alleged stock sales negate an inference of scienter due to their relative small size), and plaintiffs do not identify a contemporaneous document or witness demonstrating that Lampropoulos or Parra knew that any of their challenged statements was false when made.”

But Spaeth wrote: “Although the (consolidated class action complaint) includes some allegations related to inactionable corporate optimism and puffery, it contains sufficient allegations to state a claim for securities fraud against all defendants.” Carter agreed, denying Merit’s motion to dismiss.

Merit Medical did not immediately respond to a request for comment. This story may be updated.

Filed Under: Business/Financial News, Catheters, Featured, Legal News, Vascular Tagged With: Cianna Medical, Merit Medical Systems, Vascular Insights

In case you missed it

  • They said it at DeviceTalks Boston
  • Elucid raises $27M for heart disease diagnosis software
  • Summer health technology program brings diverse group of interns to Silicon Valley
  • BioSig expects to raise $3.5M from public offering
  • Haemonetics completes move to new Pennsylvania manufacturing facility
  • Vivera adds two industry veterans to its technology advisory board
  • Abbott Fund grants $750k to education, health equity program
  • Another Medtronic HVAD recall is serious
  • Endologix reports positive results from percutaneous bypass trial
  • NorthStar Medical names new president and chief operating officer
  • Vektor Medical names Rob Krummen as CEO
  • Baxter’s Volara lung therapy system recall is Class I
  • BD voluntarily recalls intraosseous products
  • Bioventus restructures $315M CartiHeal acquisition
  • Intrommune extends scope of Phase 1 trial for peanut-allergy-treating toothpaste
  • How SeaStar’s device calms hyperinflammation — and could prevent lasting damage from COVID cytokine storms
  • Hamilton Medical warns on some ventilators

RSS From Medical Design & Outsourcing

  • They said it at DeviceTalks Boston
    Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead. Here are some of the most quotable insights from panelists and speakers at our live event. And make sure to save the date — and save your seat… […]
  • Summer health technology program brings diverse group of interns to Silicon Valley
    Diversity by Doing HealthTech (DxD) is holding a Summer Innovation and Exploration Series for college student interns from underrepresented groups. The series is on its second day today at Fogarty Innovation and Stanford Byers Center for Biodesign — the two organizations that jointly formed and support DxD. The event debuted last year in an online… […]
  • Clippard releases new series of isolation valves
    Clippard (Cincinnati) has Its Clippard NIV Series media isolation valve — a solenoid-operated device using a flexible diaphragm to isolate the actuation mechanism from the fluid path. Media isolation valves find everyday use in a wide variety of applications. Think uses that require precise, repeatable dispensing of media for analytical instrumentation. Clippard says media isolation… […]
  • Another Medtronic HVAD recall is serious
    A year after Medtronic ceded the LVAD market to Abbott, it has yet another Class I recall involving HeartWare Ventricular Assist Device pumps still implanted in patients. The FDA today designated a Medtronic recall involving the HVADs as Class I, the most serious level. It’s the second Class I recall designation for the HVADs this… […]
  • How SeaStar’s device calms hyperinflammation — and could prevent lasting damage from COVID cytokine storms
    SeaStar Medical recently won FDA breakthrough device designation for a new way to treat hyperinflammation with technology that could help fight chronic conditions from COVID-19 infections. The Denver-based medical developer is seeking a humanitarian device exemption for treating children with acute kidney injury (AKI) based on an FDA-funded study, SeaStar President and CEO Eric Schlorff… […]
  • How Avail Medsystems seeks to create a connected OR experience
    Much like a normal Starbucks-goer expects the coffee to taste a certain way at any location, Daniel Hawkins wants that type of experience in the operating room. Hawkins is the CEO of Avail Medsystems, a company developing telemedicine equipment that can connect surgeons, interventional specialists and medical device sales reps. Hawkins and the team at Avail… […]
  • How to leverage technology to drive diversity in clinical studies
    Convenience was the driver, and the traditional clinical trial model had to evolve when it came to a colorectal cancer screening study. The clinical study had 35,000 patients across the U.S. Chuanbo Xu, Freenome Cancer doesn’t discriminate. It’s the second-leading cause of death in the U.S. Early detection is key in treating — and even… […]
  • Medical device licensing pitfalls to avoid
    Prevent costly disputes caused by these common mistakes in patent license agreements. Marcelo Barros, Kathleen Daley, Brian Kacedon and Matthew Ritter, Finnegan Licensing and other technology transfer agreements can be critical for medical device companies that invest significantly into new technology R&D and seek and obtain intellectual property protection for those investments. But if these agreements… […]
  • Tolerance stack-up: Insight into the inner workings of high-density microelectronic medical devices
    Tolerance stack-up is a defining design concept to ensure new products are built efficiently and effectively.  Darren Gilmer, Intricon At a time when the future of micro-miniature medical devices seems unlimited, one fundamental reality remains firmly in place — the sizes and shapes of human anatomy. From blood vessels to ear canals, respiratory passages to… […]
  • Deburring and finishing for beautiful, functional medical devices
    The latest automated cutting tools help medical device manufacturers meet strict specs and high demand. Dave Sawicki, Xebec Increasing demand and advances in technology are driving growth in the medical device industry. Chronic diseases are more prevalent, and the aging population is larger, contributing to the demand for highly regulated Class III medical devices such… […]
  • FDA seeking innovations to move beyond heater-cooler device problems
    The FDA issued a notice today saying that it is working to evaluate new strategies to mitigate infections associated with heater-cooler devices. According to the notice, the administration is collaborating with professional societies, public health partners, heater-cooler manufacturers, and experts on the matter surrounding the heater-cooler devices used during medical and surgical procedures to warm… […]

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS